Zevra Therapeutics, Inc. (ZVRA) News
Follow Zevra Therapeutics, Inc. (ZVRA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 21 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Form SCHEDULE 13G/A ZEVRA THERAPEUTICS, INC. Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:30 PM UTC
M
Zevra Therapeutics reports third-quarter revenue of $37.76M
Net income was $19.21M and diluted EPS was $0.26. A year earlier, revenue was $26.06M and the company reported a $544K net loss, with diluted EPS of a loss of $0.01 per share.
EQUITY | Nov 03, 2026, 10:31 PM UTC
M
Zevra Therapeutics Q3 Earnings Snapshot
Zevra Therapeutics reported third-quarter earnings.
EQUITY | Nov 03, 2026, 09:48 PM UTC
M
Zevra Therapeutics Q3 2026 Earnings Call Begins
The company's quarterly earnings call has begun.
EQUITY | Nov 03, 2026, 09:27 PM UTC
M
Zevra Therapeutics Q3 Revenue Rises 45% on MIPLYFFA Sales
EQUITY | Nov 03, 2026, 09:18 PM UTC
M
Zevra Reports Q3 2026 Financial Results and Corporate Update
Zevra reported Q3 2026 net revenue of $37.8 million, including $34.0 million from MIPLYFFA, and noted a strong cash position.
EQUITY | Nov 03, 2026, 09:13 PM UTC
L
ZVRA: Broader patient reach, data-driven growth, and global expansion drive rare disease strategy
Significant progress includes expanding the diagnosed population for MIPLYFFA, leveraging updated clinical guidelines, and investing in data-driven patient identification. Global expansion and a strong balance sheet supp
NEWS | Sep 15, 2026, 02:53 PM UTC
L
ZVRA: Broader patient identification, global expansion, and data-driven strategy fuel rare disease growth
Significant progress includes expanding the diagnosed population for MIPLYFFA, advancing global and U.S. commercialization, and leveraging robust data and updated guidelines to drive adoption. Strategic investments and a
NEWS | Sep 15, 2026, 02:39 PM UTC
L
ZVRA: Rapid U.S. growth, global expansion, and a strong pipeline drive rare disease innovation
Focused on redefining rare disease care, the company has rapidly grown its U.S. market for Niemann-Pick type C, expanded globally, and advanced a promising pipeline. Strong financials and robust patient support underpin
NEWS | Sep 14, 2026, 11:36 PM UTC
L
ZVRA: Strong U.S. growth, global expansion, and pipeline progress drive rare disease leadership
The organization is rapidly expanding its rare disease portfolio, achieving strong U.S. commercial traction in NPC, and is advancing global and pipeline initiatives. Financial strength and disciplined strategy support gr
NEWS | Sep 14, 2026, 11:28 PM UTC
L
ZVRA: Strong commercial growth, expanding rare disease reach, and robust financials drive future milestones
The organization is rapidly expanding its rare disease portfolio, with strong commercial momentum for its lead therapy, robust patient support, and a growing addressable market. Financial strength and disciplined strateg
NEWS | Sep 14, 2026, 10:33 PM UTC
L
ZVRA highlights U.S. market penetration and pipeline progress
TradingView News says a conference cited significant U.S. market penetration for NPC, robust pipeline progress including VEDS, and a long IP runway supporting rare-disease growth.
EQUITY | Sep 09, 2026, 02:13 PM UTC
L
Zevra Therapeutics executives to present at upcoming investor conferences
Zevra Therapeutics said members of its executive leadership team will present at upcoming investor conferences.
EQUITY | Sep 02, 2026, 11:37 AM UTC
L
ZVRA - Zevra Therapeutics to Present at Upcoming Investor Conferences
ZVRA - Zevra Therapeutics to Present at Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 11:30 AM UTC
L
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA in NPC
Zevra Therapeutics (ZVRA) says it will present new long-term real-world data on MIPLYFFA® for Niemann-Pick disease type C (NPC) at the 2026 SSIEM Annual Symposium.
EQUITY | Aug 25, 2026, 11:30 AM UTC
L
Zevra Therapeutics grants inducement awards under Nasdaq rule
Zevra Therapeutics says it granted inducement awards under Nasdaq Listing Rule 5635(c)(4).
REGULATION | Aug 21, 2026, 08:30 PM UTC
L
Zevra Therapeutics to Present at Conference
Zevra Therapeutics presents at growth conference
EQUITY | Aug 04, 2026, 11:30 AM UTC
M
Zevra Therapeutics Publishes Real-World Data
Zevra publishes 4-year data on MIPLYFFA in NPC
EQUITY | Aug 03, 2026, 11:30 AM UTC
L
ZVRA Reiterate Buy, though lower PT to $20 (from $29) after unfortunate European outcome @ Canaccord
ZVRA Reiterate Buy, though lower PT to $20 (from $29) after unfortunate European outcome @ Canaccord
EQUITY | Jul 27, 2026, 12:55 PM UTC
L
ZVRA -31% premarket after EMA panel issues negative opinion on Zevra arimoclomol EU marketing application for Niemann-Pick disease type C
ZVRA -31% premarket after EMA panel issues negative opinion on Zevra arimoclomol EU marketing application for Niemann-Pick disease type C
EQUITY | Jul 24, 2026, 12:08 PM UTC
M
ZVRA: Publishes Positive MIPLYFFA Data
Zevra Therapeutics announces publication of positive MIPLYFFA data from pediatric substudy in infants with Niemann-Pick Disease Type C
EQUITY | Jun 23, 2026, 11:31 AM UTC